Valeritas names Lucera as new CFO
Valeritas said last week it tapped current oncology-company Viventia Bio’s chief financial officer Erick Lucera as its new CFO, effective August 29.
Prior to holding the CFO position with Viventia Bio, Lucera operated as veep of corporate development at Aratana Therapeutics.
“Valeritas is well positioned with robust clinical data, strong reimbursement coverage and established manufacturing capacity. We are now focused on the successful execution of our capital-efficient commercial strategy. Erick’s unique background combining significant experience as a senior executive at several medical technology and biopharmaceutical companies and his deep experience as a healthcare investor will be invaluable during this execution phase as a public company,” president & CEO John Timberlake said in prepared remarks.
“Valeritas has all the important attributes of the kind of company I looked for during my investment career. V-Go has proven clinical, health and economic benefits. Most importantly, its unique design offers patients the opportunity to lead a life uninterrupted by many of the burdens of treating diabetes. The transition of the sales forces toward a capital-efficient model has put the company at an important inflection point. I am very excited to be joining the team at this moment in time,” Lucera said in a press release.